AXIM Biotechnologies, Inc. (OTC: AXIM), an innovative company focused on the research, development and production of hemp-based pharmaceutical, nutraceutical and cosmetic products with an emphasis on the well-being of their customers, announced today that it has secured the down payment on land to build a brand new, state-of-the-art facility on 6,000 square meters of land located at the industrial estate of Stichtsekant, in the city of Almere, The Netherlands. AXIM Biotech’s future high-tech factory will be located on the corner of Fort de Gagel and Fort Blauwkape.

Holding exclusive rights to the world’s first patented cannabinoid release chewing gum and, with it, plans to conduct clinical trials for pain and spasticity associated with Multiple Sclerosis (MS) set in the EU, AXIM Biotech is leading the life sciences industry with hemp-based innovations. AXIM’s focus lies in developing unique and proprietary delivery mechanisms for the introduction of cannabinoids (i.e. THC, CBD, CBG, CBN, etc.) and finding solutions for conditions for which there is currently no effective treatment including MS, spasticity, pain, Parkinson’s disease, Alzheimer’s disease/dementia, ADHD (attention deficit hyperactivity disorder), PTSD, autism, RLS (restless leg syndrome), glaucoma, IBD, IBS and Crohn’s disease.

With the first payment secured, AXIM Biotech will now begin to work with the builder and architects on detailed building and engineering plans with respect to permit applications and subsequent approvals. After the final purchase of the land, AXIM Biotech will break ground on construction.

“We are extremely grateful to the government of the province of Flevoland for allowing AXIM Biotech to establish manufacturing in Almere. The factory plans are compliant with the highest European and International standards and will produce unique pharmaceutical and nutraceutical products – all from agricultural hemp.” – Dr. George E. Anastassov, MD – Chief Executive Officer of AXIM Biotech

AXIM Biotechnologies’ state-of-the-art facility will feature a clean laboratory zone, storage areas, office and technical rooms as well as manufacturing facility furnishings. AXIM’s global manufacturing hub in Almere will have the capacity to process raw materials and manufacture the Company’s innovative hemp-based pharmaceutical, nutraceutical, and consumer products, which are all based on their own intellectual property. Project design and feasibility have begun and AXIM is targeting the completion of construction by 2017.

“This is an exciting time for life sciences as AXIM establishes a fully ‘green’ agricultural hemp-based biotech manufacturing facility. At AXIM, the hemp manufacturing byproducts will be used and result in a net negative carbon footprint that is beneficial to the environment.” – Lekhram Changoer – Chief Technical Officer of AXIM BioTech

Research shows that the industrial hemp plant can produce more than 25,000 products. Focusing on innovations in health and the environment, AXIM Biotech’s Almere facility will include manufacturing in the following product categories:

• Functional foods
• Nutraceuticals
• Pharmaceuticals
• Cosmetics
• Clean energy

Given that this facility is overseas and will be state-of-the-art, it will be interested to see how AXIM is able to impact the medical hemp markets globally and here in the United States. While completion of the facility isn’t expected until 2017, AXIM has already developed or acquired the intellectual property that could pole-vault them to the forefront of the medical hemp industry. Perhaps the most unique skew to the consumer being the time-released cannabis chewing gum, which would be the first of its kind.

What do you think about AXIM’s new facility and medical hemp development? How about the time-released cannabis gum? Join the conversation and comment below!

The post AXIM BioTech Locks Down New Medical Hemp Facility appeared first on .

Cutting-Edge Global Industrial Hemp-Based Biotechnology Company Brings Added Diversity in Food and Pharmaceuticals to MJNA’s Growing Investment Portfolio

Big news out of San Diego, California as Medical Marijuana, Inc. (OTC:MJNA) has acquired 14,943,650 shares of common stock and 500,000 shares of preferred stock in AXIM Biotechnologies, a cutting-edge biotechnology innovator. Stuart W. Titus, PhD, President and CEO of Medical Marijuana Inc. mentions: “We are extremely excited to announce our strategic ownership interest in AXIM Biotech and explain to MJNA’s shareholders some of the important innovations that Dr. Anastassov and the AXIM team are focused on. AXIM Biotech’s recent announcements include hemp-based innovations that provide consumers a wide variety of new options worldwide.”

What is AXIM Biotechnologies?

AXIM Biotech is a unique biotechnology company focused on global research, development and production of pharmaceutical, food, nutraceutical and cosmetic products as well as biofuels derived from cannabinoids. AXIM Biotech is focusing its efforts on unique proprietary mechanisms for the delivery of cannabinoids (e.g. CBD, CBG, etc.).

George E. Anastassov, MD, DDS, MBA and CEO of AXIM Biotech states, “AXIM is a unique hemp-derived biosciences corporation where the responsibility for environmental protection and conservation meets the passion for development of innovative biotechnological applications for problems for which there are currently no solutions.  The cannabis plant provides ample opportunity for innovative, and often revolutionary products. AXIM has realized the vast potential in oral health products based on cannabinoids, in particular CBG, and has filed intellectual property applications to protect its numerous IP (Intellectual Property).”

Why Get Involved with AXIM BioTech?

AXIM Biotech recently announced that it is the exclusive license recipient to the world’s first controlled-release cannabinoid chewing gum.  This opens two markets for product development and distribution: food with CanChew Plus® and pharmaceutical with MedChew RX™, which is undergoing clinical trials in preparation for registration with FDA and EMA.  The company also recently unveiled the world’s first oral care and cosmetic lines, ORAXIMAX™ and RENECANN™, containing cannabigerol (CBG).

The global pharmaceutical market is reported to be potentially worth nearly $1.6 trillion by 2020. AXIM Biotech intends to develop innovative pharmaceutical delivery systems and API (active pharmaceutical ingredients) for the treatment of conditions such as Parkinson’s disease, Alzheimer’s disease, ADHD (attention deficit hyperactivity disorder), PTSD, autism, spasticity, pain, RLS (restless leg syndrome), glaucoma, IBS, IBD, Crohn’s disease and more. All of these efforts are based on proprietary IP. Their drive and ambition is unparalleled in the space and they’re not settling until they change the healthcare industry for the better!

Additional markets where AXIM Biotech intends to play a significant role are:

• Nutraceutical – Global Potential $207 Billion by 2016
• Phytoplant/Botanicals – Global Current Market $83 Billion
• R&D – Drug Discovery a Global $25 Billion Market
• Alternative Energy – Global Biofuels $185.3 Billion by 2021
• Manufacturing – 16% of Global GDP and Growing

Who is behind AXIM Biotechnologies?

Leading AXIM Biotechnologies is an international executive team of highly skilled and specialized professionals. Its members are responsible for the company’s strategic initiatives and global operations. Through various committees, they oversee operations and business performance, strategy and planning, future and current product manufacturing, risk management, research and development, external affairs, and internal governance.

Dr. George E. Anastassov, MD, DDS, MBA – Chief Executive Officer

Dr. Philip A. Van Damme, DMD, MD, PhD – Chief Medical Officer

Lekhram Changoer, MSc. BSc. – Chief Technology Officer

AXIM Biotechnologies’ industry-leading advisory board is composed of world leaders in their respective fields. AXIM’s Board of Advisors provides the Company with extensive expertise.

Members of the AXIM Board of Advisors include: Professor Renger Witkamp, Professor John Zajicek, Prof. Jacques Meis, Dr. Arno Hazekamp, Warren Hutchins, and Dr. Murad A. Sunalp.

You May Have Heard of AXIM Biotech?

AXIM Biotech has been featured by media outlets including: FOX Business, MainStreet.com, MJ Freeway, Chemical & Engineering News, Dental Tribune, Pharmaceutical Commerce, Dental Products Report and MJI News.

To learn more about the company, visit AXIM Biotech’s website.

Who is Medical Marijuana, Inc?

Medical Marijuana Inc.’s goal is to be the premier hemp industry innovators, leveraging their team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. They strive to create awareness within the industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For more information, you can visit the company’s website at: www.MedicalMarijuanaInc.com.

What do you think about this acquisition? How about the worlds first controlled-release cannabinoid chewing gum? Join the conversation and comment below!

The post Medical Marijuana, Inc. Announces Investment in AXIM Biotechnologies appeared first on .